[ad_1]
PARIS–(FILO D & # 39; BUSINESS) – Announced Servier, an independent international pharmaceutical company
today which has joined the Blockchain Health Consortium of Embleema, a
decentralized network based on Blockchain technology, as part of the
launch of a blockchain pilot project within the Group. Emblem of
Blockchain Health Consortium, which brings together the patient
associations, societies of life sciences and health workers,
offers patients the opportunity to share digital health data in real time
time to inform clinical research, allowing better patient involvement and
monitoring their data in real life.
As part of the consortium, Servier will contribute to the construction
of the decentralized network Blockchain Emblem, which houses a hub
servers to securely store and share data and use the network
guarantee the security of sensitive data. This pilot project will be executed for
one year and aims to define and evaluate an operational process first
considering the implementation of technology on a larger scale.
"A considerable amount of health data is generated every day, including
from the patients themselves through, for example, connected objects. This data is
an inestimable source of knowledge to accelerate the discovery of new ones
therapeutic solutions. In this context, Blockchain is seen as a key
technology in creating a more collaborative model between
health professionals and patients ", commented Olivier Laureau,
President of Servier. "That's why we're excited to contribute, inside
the Health Blockchain Emblem Consortium, to build this
new model that reflects the Group's commitment to putting patients
needs at the center of all its activities ".
Robert Chu, CEO of Embleema added: "The blockchain for the health of Embleema allows
patients to own their data and allows better accessibility and
transparency of real-world data to accelerate drug development and
ultimately bringing personalized therapies to patients as soon as possible. We are
pleased to welcome Servier into our Health Blockchain Consortium, e
I look forward to our cooperation to improve patient engagement and data
sharing. "
The objectives of the Consortium align with the objectives outlined by the 21st
Century Cures Act, a health bill signed by US law in 2016, which
gives the FDA a mandate to accelerate regulatory approval for new ones
treatments that incorporate patient and real-world perspectives
reporting of test data. This has led life science companies to
integrate real world trials (RWE) into clinical trials, including
Electronic Health Records (EHR), results reported by the patient and connected
health sensors.
About Servier
Servier is an international pharmaceutical company governed by a
non-profit foundation, based in France (Suresnes). With
a strong international presence in 149 countries and a turnover of 4,152
billions of euros in 2017, Servier employs 21,700 people worldwide. Entirely
independent, the Group reinvests 25% of its turnover (princeps drugs) a
research and development and use all its profits for development.
Corporate growth is driven by Servier's constant innovation research
in five areas of excellence: cardiovascular, immune-inflammatory and
neuropsychiatric diseases, cancer and diabetes as well as from his
activities in high quality generic drugs. Servier also offers eHealth
solutions beyond drug development.
Further information: www.servier.com
Follow us on social media: LinkedIn,
Facebook,
chirping
About Emblem
Emblem is
the patient-led health blockchain network for the secure sharing of
personal medical records. Hosted on a private block of Ethereum,
The consolidated and highly secure repository of Embleema provides the
health ecosystem with an undisputed and holistic view of patients
medical history, Embleema is creating decentralized health data
economy by linking key stakeholders in the health sector,
directly with patients while maintaining patient data sovereignty.
For more information, visit www.embleema.com e
follow Emblem on Twitter @Embleema, Telegram, LinkedIn,
and Facebook.
[ad_2]Source link
